drugset / Trial / NCT05260359
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
Non-randomizedSingle-groupSingle-blindScreening
Summary
The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
Timeline
- Start
- 2022-02-23
- Primary completion
- 2022-04-08
- Completion
- 2022-04-08
Publications
- Background McNamee PM, Api AM, Basketter DA, Frank Gerberick G, Gilpin DA, Hall BM, Jowsey I, Robinson MK. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Regul Toxicol Pharmacol. 2008 Oct;52(1):24-34. doi: 10.1016/j.yrtph.2007.10.019. Epub 2007 Dec 4.
- Background Api AM, Vey M. Implementation of the dermal sensitization Quantitative Risk Assessment (QRA) for fragrance ingredients. Regul Toxicol Pharmacol. 2008 Oct;52(1):53-61. doi: 10.1016/j.yrtph.2008.05.011. Epub 2008 May 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bemotrizinol | Unknown | 6 % | Topical |